Sanofi (SNY) Q3 2025: New Launches Drive 41% Sales Surge, Offsetting Vaccine Headwinds
Sanofi’s Q3 2025 performance was defined by robust momentum from new launches, which now comprise 15% of total sales and delivered 41% growth, counterbalancing softness in vaccines and currency headwinds. The company’s disciplined cost management and product mix improvements supported margin expansion, while management reiterated full-year guidance and signaled confidence in sustaining profitable growth into 2026. Investors should focus on the trajectory of Dupixent, the evolving vaccine landscape, and the execution risks tied to pipeline advancement and upcoming royalty step-downs.
Summary
- Launch Portfolio Expansion: New medicines and vaccines accelerated growth and now represent a rising share of total sales.
- Vaccine Segment Drag: Competitive pricing and flu vaccine fatigue weighed on overall vaccine performance despite respiratory product gains.
- Profitability Outlook: Management signaled ongoing gross margin improvement and EPS growth, but flagged a 2027 royalty gap risk.
Business Overview
Sanofi is a global biopharmaceutical company generating revenue through prescription pharmaceuticals, vaccines, and consumer healthcare. Its major segments are Pharmaceuticals (including Immunology, Rare Diseases, Oncology, and General Medicines), Vaccines, and Consumer Healthcare. Growth is currently powered by immunology (notably Dupixent, a biologic for inflammatory diseases) and a slate of recent launches, while vaccines and legacy businesses provide scale and global reach.
Performance Analysis
Sanofi reported 7% constant-currency sales growth in Q3 2025, led by strong execution in the pharmaceuticals segment and especially by immunology and new product launches. Notably, Dupixent surpassed €4 billion in quarterly sales for the first time, with patient growth over 30% YoY and robust expansion in both the US and ex-US markets. New launches contributed €1.8 billion, up 41% YoY, and now account for 15% of total sales, nearly half the size of Dupixent’s sales base.
Conversely, the vaccine segment saw a decline, pressured by competitive price dynamics in Germany and lower flu vaccination rates in the US, as well as inventory phasing. Respiratory vaccine Bay Fortis continued to expand globally, offsetting some of the vaccine softness. Gross margin improved by 2.3 percentage points, supported by product mix, operational productivity, and the completion of Dupixent’s C3 manufacturing transition. Operating expenses rose 6%, but excluding M&A impacts, underlying cost growth remained in the low single digits, reflecting ongoing cost discipline.
- Launches as Growth Engine: New products now represent a material and accelerating share of total sales, driving top-line momentum.
- Vaccine Volatility: Segment underperformed due to pricing and demand softness, highlighting exposure to external market swings.
- Margin Leverage: Product mix and operational efficiencies drove margin improvement, with volume growth and new launches as key contributors.
Sanofi’s business EPS outpaced sales growth, reflecting positive operating leverage. Management reiterated full-year guidance for both sales and EPS growth, underpinned by year-to-date performance and Q4 expectations for the strongest quarter of the year.
Executive Commentary
"Our launches delivered 1.8 billion euros this quarter, through more than 40%, and now represent 15% of our total sales. To put this in perspective, our launches represent almost half of Dupixent's sales this quarter, demonstrating their significant contribution to our growth."
Paul Hudson, Chief Executive Officer
"Our business growth margin increased by 2.3 percentage points this quarter, with a continued improvement in product mix, enhanced by productivity gains. We now capture the full benefit of DuPixent's improved manufacturing process."
François, Chief Financial Officer
Strategic Positioning
1. Launch Portfolio as a Structural Growth Lever
Sanofi’s new launches, including Avakit (systemic mastocytosis), Nivaxavit (protein-based COVID-19 vaccine), and Wayrills (BTK inhibitor for immune thrombocytopenia), are now a core growth driver. This pipeline-to-commercial execution is shifting the company’s revenue mix toward higher-margin, innovative therapies, reducing dependence on legacy products.
2. Immunology Franchise Deepening
Dupixent, a biologic for inflammatory diseases, has extended its leadership with new indications (COPD, CSU, BP) and continued global expansion. The company is actively investing in lifecycle management and next-generation immunology assets, aiming to sustain growth as biosimilar and competitive threats emerge.
3. Vaccine Business Under Pressure and Pivoting
Vaccine results reflected external headwinds, including price competition and lower flu uptake. However, Sanofi is investing in differentiated offerings, such as high-dose flu vaccines and RSV prevention, and advancing flu-COVID combination candidates, aiming to restore growth and defend its leadership in key vaccine categories.
4. Cost Discipline and Margin Expansion
Operating expense control, especially in G&A, and product mix improvements are supporting margin expansion. The company is guiding to stable G&A and continued investment in R&D and commercial support for launches, balancing growth and profitability.
5. Capital Allocation and Royalty Dynamics
Sanofi continues to pursue selective bolt-on M&A, maintain progressive dividends, and execute opportunistic buybacks. However, the company flagged a material step-down in Regeneron R&D reimbursements and royalty flows in 2027, which will require operational offset to sustain profitability.
Key Considerations
Q3 2025 marked a strategic inflection for Sanofi, with new launches and immunology driving growth but vaccine headwinds and future royalty step-downs introducing new complexity.
Key Considerations:
- Launch Sustainability: Continued uptake and geographic expansion of new medicines will be critical to offsetting legacy erosion and vaccine cyclicality.
- Vaccine Market Risks: Pricing power and demand for flu and other vaccines remain volatile, with competitive entries and “vaccine fatigue” impacting volumes and margins.
- Margin Structure Evolution: Product mix and operational leverage are currently supporting margin gains, but these effects may moderate as manufacturing transitions normalize.
- Royalty and Reimbursement Headwinds: The anticipated €500 million EBIT gap in 2027 from Regeneron reimbursement step-down is a looming challenge, with limited levers to fully offset.
- Pipeline Execution: Timely advancement, regulatory approvals, and successful commercialization of late-stage assets are essential to maintaining growth and investor confidence.
Risks
Sanofi faces significant risks from external pricing pressures, especially in vaccines, regulatory and reimbursement uncertainty in the US and EU, and the impending loss of Regeneron R&D reimbursements in 2027. Pipeline execution risks remain, as late-stage setbacks or delays could undermine the growth narrative. Investors should also monitor the company’s ability to sustain launch momentum and offset legacy and royalty drags with new product contributions.
Forward Outlook
For Q4 2025, Sanofi guided to:
- Strongest sales and EPS quarter of the year, with growth exceeding prior quarters
- Continued operating leverage as launches ramp and cost discipline persists
For full-year 2025, management reiterated guidance:
- Mid single-digit sales growth at constant exchange rates
- Low double-digit business EPS growth, with margin expansion
Management highlighted several factors that will shape results:
- Launch ramp and pipeline milestones in immunology and rare diseases
- Vaccine segment stabilization and new product introductions
Takeaways
- Launch Momentum Offsets Legacy Drag: New launches and Dupixent growth are structurally shifting the revenue base, supporting margin expansion and profitability even as vaccines underperform.
- Vaccine and Royalty Headwinds Loom: Near-term vaccine softness and the 2027 Regeneron royalty step-down present material challenges that will require operational and pipeline execution to overcome.
- Investors Should Watch Pipeline and Margin Trends: The sustainability of margin gains, pipeline advancement, and the ability to deliver on EPS growth targets will be decisive for the stock’s forward trajectory.
Conclusion
Sanofi’s Q3 2025 results highlight a business in transition, with new launches and immunology driving profitable growth amid vaccine headwinds and looming royalty risks. The company’s ability to sustain launch momentum, execute on pipeline milestones, and manage margin structure will be central to its long-term investment case.
Industry Read-Through
Sanofi’s quarter underscores a broader biopharma pivot: durable growth is increasingly reliant on successful new product launches and lifecycle management, as legacy franchises face price and demand headwinds. Vaccine market volatility and “vaccine fatigue” are industry-wide challenges, pressuring not only Sanofi but also peers with significant flu and respiratory vaccine exposure. The highlighted royalty step-downs and cost discipline themes are relevant for large-cap pharma navigating patent cliffs and external partnership economics. Operational leverage from product mix and cost control remains a key differentiator, but sustainability will depend on continuous pipeline execution and successful launch commercialization across the sector.